Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 3
2004 3
2005 3
2007 1
2008 5
2009 4
2010 5
2011 4
2012 3
2013 1
2014 3
2015 3
2016 7
2017 4
2018 7
2019 2
2020 3
2021 3
2022 5
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Trappe RU, et al. Among authors: hauser ia. J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19. J Clin Oncol. 2017. PMID: 27992268 Clinical Trial.
Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Nashan B, Thaiss F. Sommerer C, et al. Among authors: hauser ia. Trials. 2016 Feb 17;17:92. doi: 10.1186/s13063-016-1220-9. Trials. 2016. PMID: 26888217 Free PMC article. Clinical Trial.
Pparγ Expression in T Cells as a Prognostic Marker of Sepsis.
Brenneis M, Aghajaanpour R, Knape T, Sha LK, Neb H, Meybohm P, Zacharowski K, Hauser IA, Büttner S, Parnham MJ, Brüne B, von Knethen A. Brenneis M, et al. Among authors: hauser ia. Shock. 2016 Jun;45(6):591-7. doi: 10.1097/SHK.0000000000000568. Shock. 2016. PMID: 26796570
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.
Schaier M, Morath C, Wang L, Kleist C, Opelz G, Tran TH, Scherer S, Pham L, Ekpoom N, Süsal C, Ponath G, Kälble F, Speer C, Benning L, Nusshag C, Mahler CF, Pego da Silva L, Sommerer C, Hückelhoven-Krauss A, Czock D, Mehrabi A, Schwab C, Waldherr R, Schnitzler P, Merle U, Schwenger V, Krautter M, Kemmner S, Fischereder M, Stangl M, Hauser IA, Kälsch AI, Krämer BK, Böhmig GA, Müller-Tidow C, Reiser J, Zeier M, Schmitt M, Terness P, Schmitt A, Daniel V. Schaier M, et al. Among authors: hauser ia. Front Immunol. 2023 Jul 11;14:1089664. doi: 10.3389/fimmu.2023.1089664. eCollection 2023. Front Immunol. 2023. PMID: 37483623 Free PMC article. Clinical Trial.
65 results